PAK6在前列腺癌中的表达及临床意义

Expression and clinical significance of PAK6 in prostate cancer

目的:比较P21活化激酶6(PAK6)在前列腺癌和前列腺增生组织中的表达和探讨PAK6表达在前列腺癌临床分期的意义。方法:采用免疫组织化学染色方法,检测42例前列腺癌及46例前列腺增生石蜡包埋组织中PAK6的表达。结果:PAK6在前列腺增生组织和前列腺癌组织中均有阳性表达,前列腺癌组织中PAK6阳性表达及表达强度均明显高于前列腺增生组织,有显著性差异。42例前列腺癌中临床分期Ⅲ-Ⅳ期的患者共20例,Ⅰ-Ⅱ期的患者22例,两者的PAK6蛋白表达率无明显差异,但临床分期Ⅲ-Ⅳ期的PAK6表达强度明显高于临床Ⅰ-Ⅱ期患者,有显著性差异。结论:PAK6蛋白在前列腺癌中有明显的表达,与前列腺癌的局部侵袭和远处转移相关,对肿瘤的临床分期与预后有一定的预测作用。

Objective To compare the expression of P21 activated Kinase 6(PAK6)in prostate cancer(PCa)and benign prostatic hyperplasia(BPH)and to explore the significance of PAK6 expression in clinical staging of PCa.Methods The expression of PAK6 in paraffin-embedded tissues of 42 cases of prostate cancer and 46 cases of benign prostatic hyperplasia was detected by immunohistochemical staining.Results PAK6 expression was positive in BPH and PCa,but the expression and intensity of PAK6 in prostate cancer were significantly higher than that in BPH.There was no significant difference in PAK6 expression between the 42 PCa patients with stageⅢ-Ⅳand stageⅠ-Ⅱ,but PAK6 expressive intensity in stageⅢ-Ⅳwas significantly higher than that in stageⅠ-Ⅱ,there was significant difference.Conclusion PAK6 protein was significantly expressed in prostate cancer,which was associated with local invasion and distant metastasis.PAK6 protein could predict the clinical stage and prognosis of prostate cancer.